The algorithm, developed by data scientists and physicians from Anumana, Janssen and the Mayo Clinic, automatically analyzes ECG readings to predict the likelihood that a patient will be diagnosed with pulmonary hypertension.
Fierce Biotech
By Andrea Park
May 27, 2022
(Pixabay/PublicDomainPictures)
Though it affects only somewhere between 0.1% and 1% of the world’s population, pulmonary hypertension can carry an outsized mortality risk.
That’s due to its largely nonspecific symptoms — including shortness of breath, heart palpitations and fatigue — which can significantly stretch out the time between when symptoms first appear and a doctor is finally able to link them to a definitive diagnosis and begin treating the condition.
A new artificial intelligence algorithm may be the key to slashing that drawn-out prediagnosis period.
It was developed by a group of data scientists and physicians representing
- Johnson & Johnson’s Janssen Research & Development,
- the Mayo Clinic and
- nference spinout Anumana,
and it’s designed to spot signs of pulmonary hypertension in electrocardiogram readings.
The algorithm is already in the FDA’s good graces.
It’s been granted the agency’s breakthrough device designation, the partners announced this week, clearing away some of the obstacles in its path toward a full regulatory clearance.
Originally published at https://www.fiercebiotech.com
